[{"id":"36ca1f5c-c2f6-4841-9b20-252eb2f23150","acronym":"","url":"https://clinicaltrials.gov/study/NCT04987996","created_at":"2021-08-03T18:52:59.526Z","updated_at":"2024-07-02T16:35:46.330Z","phase":"Phase 2","brief_title":"GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients","source_id_and_acronym":"NCT04987996","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" CD8 • IL2RA • CCR7 • CD27 • LGALS3 • FAS • FOXP3 • ISG20","pipe":"","alterations":" ","tags":["CD8 • IL2RA • CCR7 • CD27 • LGALS3 • FAS • FOXP3 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • belapectin (GR-MD-02)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2031","study_completion_date":" 07/01/2031","last_update_posted":"2023-06-06"},{"id":"eed65522-feef-4cd9-a62e-7dcfa9be2400","acronym":"","url":"https://clinicaltrials.gov/study/NCT02575404","created_at":"2021-01-18T12:29:00.661Z","updated_at":"2024-07-02T16:35:46.551Z","phase":"Phase 1","brief_title":"GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients","source_id_and_acronym":"NCT02575404","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" BRAF • CD4","pipe":"","alterations":" ","tags":["BRAF • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • belapectin (GR-MD-02)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 05/16/2016","start_date":" 05/16/2016","primary_txt":" Primary completion: 01/12/2021","primary_completion_date":" 01/12/2021","study_txt":" Completion: 10/10/2022","study_completion_date":" 10/10/2022","last_update_posted":"2023-06-05"}]